667, L.P.

667, L.P. has an estimated net worth of $16.2 Billion. This is based on reported shares across multiple companies, which include BeiGene, Ltd., Prelude Therapeutics Inc, Kiniksa Pharmaceuticals International, plc, Zymeworks Inc., IGM Biosciences, Inc., Kodiak Sciences Inc., IDERA PHARMACEUTICALS, INC., DBV Technologies S.A., TScan Therapeutics, Inc., Neurogene Inc., Aeglea BioTherapeutics, Inc., ACADIA PHARMACEUTICALS INC, XOMA Corp, Talis Biomedical Corp, Seagen Inc., INCYTE CORP, ALEXION PHARMACEUTICALS, INC., MADRIGAL PHARMACEUTICALS, INC., SYNAGEVA BIOPHARMA CORP, Mirati Therapeutics, Inc., GENOMIC HEALTH INC, BIOCRYST PHARMACEUTICALS INC, vTv Therapeutics Inc., Kymera Therapeutics, Inc., BICYCLE THERAPEUTICS PLC, Immunocore Holdings plc, Replimune Group, Inc., and Denali Therapeutics Inc..

2016 was 667, L.P.'s most active year for acquiring shares with 359 total transactions. 667, L.P.'s most active month to acquire stocks was the month of May. 2019 was 667, L.P.'s most active year for disposing of shares, totalling 369 transactions. 667, L.P.'s most active month to dispose stocks was the month of October. 2013 saw 667, L.P. paying a total of $53,699,125,055.99 for 548,093,129 shares, this is the most they've acquired in one year. In 2013 667, L.P. cashed out on 117,349,500 shares for a total of $49,999,570,365.60, their largest year based on trade value.